Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

Karyopharm Aims For Xpovio Myelofibrosis Approval Despite Endpoint Miss

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY ...

Karyopharm's Phase III myelofibrosis trial delivers mixed results

Reduced Spleen Volume Observed in Topline Selinexor/Ruxolitinib Trial Results

Karyopharm's Phase III myelofibrosis trial delivers mixed results

Selinexor Plus Ruxolitinib Hits SVR Primary End Point in Myelofibrosis

Karyopharm posts trial win for Xpovio in myelofibrosis (KPTI)

Phase 3 SENTRY Trial Shows Progress in Myelofibrosis Care

Myelofibrosis Treatment Landscape Is Poised for Change

Karyopharm myeloma drug yields mixed data in myelofibrosis trial

Selinexor Combo Hits Spleen Target, Misses Symptom Endpoint in Myelofibrosis

Can mixed results gain an expansion for Karyopharm's Expovio?

Karyopharm research and financing developments

Pharmacist-Led Interventions Improve Medication Management for Patients Receiving ...

Karyopharm gets an Xpovio blow | ApexOnco

Karyopharm Discloses Data From Trial of Blood-Cancer Treatment; $30 Million Private Placement

Karyopharm eyes Xpovio filing in myelofibrosis on mixed data

Karyopharm Therapeutics SENTRY Trial Hits Spleen Endpoint, Shows Early Survival Signal ...

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint ...

Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis

Log in to enable infinite scrolling